Tests conducted in Brazil by the World Health Organization (WHO) have shown that fluoxetine, a common and low-cost antidepressant drug, also reduces the severity of the coronavirus.
Trials of the drug in Brazil continued from January 15 to August 6 this year under the UN’s Together program, overseen by a panel of World Health Organization experts.
According to a report published in the latest issue of the research journal The Lancet Global Health, the trials involved 1472 patients who had been diagnosed at an early stage of coronary heart disease.
Of these, 739 patients were given two tablets of the original fluvoxamine 100 mg daily for ten days. The remaining 733 were given another harmless pill (placebo) in the same order, monitoring each patient for 28 days after use. I was placed to monitor the severity of the disease or not.
According to the report, patients who used real fluvoxamine had a 30% lower hospitalization rate due to Covid 19. In contrast, patients who were taking fluvoxamine and other medications had a 65% lower rate. Percent is less.
The Lancet Global Health report also states that fluvoxamine should be used in the treatment of Covid 19 only on the advice of a doctor.
It should be noted that the US Drug Enforcement Administration (FDA) had approved fluoxetine in 2007 for the treatment of depression, which is widely available in the world, including Pakistan, under various trade names.